Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday for the first time since the launch of its Wegovy ...

Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions ...

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...

It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly ...

Eli Lilly has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug Wegovy ...

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

CVS Health ( NYSE: CVS) on Thursday announced plans to discontinue operations in the individual health insurance business, ...

The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

The FTSE 100 ended Thursday marginally higher by 0.02%, continuing its winning streak to be on par with its run in 2017.